Related references
Note: Only part of the references are listed.EV-101: A Phase I Study of Single-Agent Enfortumab Vedotin in Patients With Nectin-4-Positive Solid Tumors, Including Metastatic Urothelial Carcinoma
Jonathan Rosenberg et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Combination Intravesical Therapy
Nathan A. Brooks et al.
UROLOGIC CLINICS OF NORTH AMERICA (2020)
Salvage Therapy for Non-muscle-invasive Bladder Cancer: Novel Intravesical Agents
Dunia Khaled et al.
UROLOGIC CLINICS OF NORTH AMERICA (2020)
Urothelial carcinoma: the development of FGFR inhibitors in combination with immune checkpoint inhibitors
Qian Qin et al.
EXPERT REVIEW OF ANTICANCER THERAPY (2020)
Erdafitinib for the treatment of metastatic bladder cancer
Kamaneh Montazeri et al.
EXPERT REVIEW OF CLINICAL PHARMACOLOGY (2020)
Targeting the Src Pathway Enhances the Efficacy of Selective FGFR Inhibitors in Urothelial Cancers with FGFR3 Alterations
Nadia Carvalho Lima et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)
Study EV-103: Durability results of enfortumab vedotin plus pembrolizumab for locally advanced or metastatic urothelial carcinoma.
Jonathan E. Rosenberg et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Management of Muscle-invasive Bladder Cancer in the 2020s: Challenges and Perspectives
Georgios Gakis
European Urology Focus (2020)
Obatoclax, a BH3 Mimetic, Enhances Cisplatin-Induced Apoptosis and Decreases the Clonogenicity of Muscle Invasive Bladder Cancer Cells via Mechanisms That Involve the Inhibition of Pro-Survival Molecules as Well as Cell Cycle Regulators
Thomas M. Steele et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)
CCDC6 and USP7 expression levels suggest novel treatment options in high-grade urothelial bladder cancer
Francesco Morra et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2019)
New combinatorial strategies to improve the PARP inhibitors efficacy in the urothelial bladder Cancer treatment
Daniela Criscuolo et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2019)
Inhibition of PI3K pathway increases immune infiltrate in muscle-invasive bladder cancer
Edith Borcoman et al.
ONCOIMMUNOLOGY (2019)
Use of targeted next generation sequencing to characterize tumor mutational burden and efficacy of immune checkpoint inhibition in small cell lung cancer
Biagio Ricciuti et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)
Emerging Immunotherapy Options for bacillus Calmette-Guerin Unresponsive Nonmuscle Invasive Bladder Cancer
Maxwell V. Meng et al.
JOURNAL OF UROLOGY (2019)
Combination of androgen receptor inhibitor and cisplatin, an effective treatment strategy for urothelial carcinoma of the bladder
Ashish Tyagi et al.
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS (2019)
Management of metastatic bladder cancer
Rosa Nadal et al.
CANCER TREATMENT REVIEWS (2019)
Novel Oral mTORC1/2 Inhibitor TAK-228 Has Synergistic Antitumor Effects When Combined with Paclitaxel or PI3Kα Inhibitor TAK-117 in Preclinical Bladder Cancer Models
Anna Hernandez-Prat et al.
MOLECULAR CANCER RESEARCH (2019)
European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (TaT1 and Carcinoma In Situ)-2019 Update
Marko Babjuk et al.
EUROPEAN UROLOGY (2019)
An update on immunotherapy options for urothelial cancer
Burak Bilgin et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2019)
CTLA-4 (CD152): A versatile receptor for immune-based therapy
Holger Lingel et al.
SEMINARS IN IMMUNOLOGY (2019)
Discerning Patterns and Quality of Neoadjuvant Chemotherapy Use Among Patients with Muscle-invasive Bladder Cancer
Jinhai Huo et al.
EUROPEAN UROLOGY ONCOLOGY (2019)
Targeted therapies for advanced bladder cancer: new strategies with FGFR inhibitors
Chiara Casadei et al.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY (2019)
Combining Immunotherapy with Radiotherapy for the Treatment of Genitourinary Malignancies
Abhishek A. Solanki et al.
EUROPEAN UROLOGY ONCOLOGY (2019)
The Current Status and Future Role of the Phosphoinositide 3 Kinase/AKT Signaling Pathway in Urothelial Cancer: An Old Pathway in the New Immunotherapy Era
Sandy T. Liu et al.
CLINICAL GENITOURINARY CANCER (2018)
Anti-Programmed Cell Death 1/Ligand 1 (PD-1/PD-L1) Antibodies for the Treatment of Urothelial Carcinoma: State of the Art and Future Development
Thomas Powles et al.
CLINICAL GENITOURINARY CANCER (2018)
Molecular targeted therapy: Treating cancer with specificity
Yeuan Ting Lee et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2018)
Dose-limiting Urinary Toxicity With Pembrolizumab Combined With Weekly Hypofractionated Radiation Therapy in Bladder Cancer
Alison Claire Tree et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2018)
Biomarkers of immunotherapy in urothelial and renal cell carcinoma: PD-L1, tumor mutational burden, and beyond
Jason Zhu et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2018)
Bladder Cancer: New Insights into Its Molecular Pathology
Kentaro Inamura
CANCERS (2018)
Epacadostat Plus Pembrolizumab in Patients With Advanced Solid Tumors: Phase I Results From a Multicenter, Open-Label Phase I/II Trial (ECHO-202/KEYNOTE-037)
Tara C. Mitchell et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Development of PARP and Immune-Checkpoint Inhibitor Combinations
Ross A. Stewart et al.
CANCER RESEARCH (2018)
PARP Inhibition Elicits STING-Dependent Antitumor Immunity in Brca1-Deficient Ovarian Cancer
Liya Ding et al.
CELL REPORTS (2018)
High and low mutational burden tumors versus immunologically hot and cold tumors and response to immune checkpoint inhibitors
Saman Maleki Vareki
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2018)
Role of Checkpoint Inhibition in Localized Bladder Cancer
Noah M. Hahn et al.
EUROPEAN UROLOGY ONCOLOGY (2018)
Antibody-Drug Conjugates in Bladder Cancer
Panagiotis J. Vlachostergios et al.
BLADDER CANCER (2018)
Non-muscle-invasive bladder cancer: Intravesical treatments beyond Bacille Calmette-Guerin
Vignesh T. Packiam et al.
CANCER (2017)
Next-generation Sequencing of Nonmuscle Invasive Bladder Cancer Reveals Potential Biomarkers and Rational Therapeutic Targets
Eugene J. Pietzak et al.
EUROPEAN UROLOGY (2017)
A phase I/II trial of fixed-dose stereotactic body radiotherapy with sequential or concurrent pembrolizumab in metastatic urothelial carcinoma: evaluation of safety and clinical and immunologic response
Nora Sundahl et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2017)
Immunotherapy for the Treatment of Urothelial Carcinoma
Nicholas M. Donin et al.
JOURNAL OF UROLOGY (2017)
Epigenetics and immunotherapy: The current state of play
Jennifer Dunn et al.
MOLECULAR IMMUNOLOGY (2017)
DNA Damage and Repair Biomarkers of Immunotherapy Response
Kent W. Mouw et al.
CANCER DISCOVERY (2017)
NVP-BEZ235 synergizes cisplatin sensitivity in osteosarcoma
Jin-Cheng Huang et al.
Oncotarget (2017)
No patient left behind: The promise of immune priming with epigenetic agents
Corey A. Carter et al.
ONCOIMMUNOLOGY (2017)
The Phosphatidylinositol 3-Kinase Pathway as a Potential Therapeutic Target in Bladder Cancer
Shu-Xiong Zeng et al.
CLINICAL CANCER RESEARCH (2017)
Inhibition of PI3K/Akt/mTOR overcomes cisplatin resistance in the triple negative breast cancer cell line HCC38
Katharina Gohr et al.
BMC CANCER (2017)
Comprehensive Molecular Characterization of Muscle-Invasive Bladder Cancer
A. Gordon Robertson et al.
CELL (2017)
Expression of Indoleamine 2,3-Dioxygenase Gene Is a Feature of Poorly Differentiated Non- muscle-invasive Urothelial Cell Bladder Carcinomas
Tvrtko Hudolin et al.
ANTICANCER RESEARCH (2017)
Intravesical gemcitabine in combination with mitomycin C as salvage treatment in recurrent non-muscle-invasive bladder cancer
Patrick A. Cockerill et al.
BJU INTERNATIONAL (2016)
Loss of PTEN Promotes Resistance to T Cell-Mediated Immunotherapy
Weiyi Peng et al.
CANCER DISCOVERY (2016)
Phase II study of dual phosphoinositol-3-kinase (PI3K) and mammalian target of rapamycin (mTOR) inhibitor BEZ235 in patients with locally advanced or metastatic transitional cell carcinoma
Emmanuel Seront et al.
BJU INTERNATIONAL (2016)
Immune checkpoint blockade: Releasing the brake towards hematological malignancies
Yi Xia et al.
BLOOD REVIEWS (2016)
PIK3CA dependence and sensitivity to therapeutic targeting in urothelial carcinoma
R. L. Ross et al.
BMC CANCER (2016)
Systematic review of case reports on the abscopal effect
Yazan Abuodeh et al.
CURRENT PROBLEMS IN CANCER (2016)
Sequential bacillus Calmette-Guerin/Electromotive Drug Administration of Mitomycin C as the Standard Intravesical Regimen in High Risk Nonmuscle Invasive Bladder Cancer: 2-Year Outcomes
Christine Gan et al.
JOURNAL OF UROLOGY (2016)
A novel hypoxia-selective epigenetic agent RRx-001 triggers apoptosis and overcomes drug resistance in multiple myeloma cells
D. S. Das et al.
LEUKEMIA (2016)
Interdependent IL-7 and IFN-γ signalling in T-cell controls tumour eradication by combined α-CTLA-4+α-PD-1 therapy
Lewis Zhichang Shi et al.
NATURE COMMUNICATIONS (2016)
IL-15 superagonist/IL-15RαSushi-Fc fusion complex (IL-15SA/IL-15RαSu-Fc; ALT-803) markedly enhances specific subpopulations of NK and memory CD8+ T cells, and mediates potent anti-tumor activity against murine breast and colon carcinomas
Peter S. Kim et al.
ONCOTARGET (2016)
Molecular Drivers of the Non-T-cell-Inflamed Tumor Microenvironment in Urothelial Bladder Cancer
Randy F. Sweis et al.
CANCER IMMUNOLOGY RESEARCH (2016)
Immunotherapy in Bladder Cancer
Monali Vasekar et al.
CURRENT MOLECULAR PHARMACOLOGY (2016)
Preclinical Development of Ipilimumab and Nivolumab Combination Immunotherapy: Mouse Tumor Models, In Vitro Functional Studies, and Cynomolgus Macaque Toxicology (vol 11, e0161779, 2016)
Mark J. Selby et al.
PLOS ONE (2016)
The role of PD-L1 in the radiation response and clinical outcome for bladder cancer
Chun-Te Wu et al.
SCIENTIFIC REPORTS (2016)
An Epigenomic Approach to Improving Response to Neoadjuvant Cisplatin Chemotherapy in Bladder Cancer
Evanguelos Xylinas et al.
BIOMOLECULES (2016)
Global Cancer Statistics, 2012
Lindsey A. Torre et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2015)
Comparative effectiveness of gemcitabine plus cisplatin versus methotrexate, vinblastine, doxorubicin, plus cisplatin as neoadjuvant therapy for muscle-invasive bladder cancer
Matthew D. Galsky et al.
CANCER (2015)
A Systematic Review of Immunotherapy in Urologic Cancer: Evolving Roles for Targeting of CTLA-4, PD-1/PD-L1, and HLA-G
Edgardo D. Carosella et al.
EUROPEAN UROLOGY (2015)
Sequential Combination of Mitomycin C Plus Bacillus Calmette-Guerin (BCG) Is More Effective but More Toxic Than BCG Alone in Patients with Non-Muscle-invasive Bladder Cancer in Intermediate-and High-risk Patients: Final Outcome of CUETO 93009, a Randomized Prospective Trial
Eduardo Solsona et al.
EUROPEAN UROLOGY (2015)
Anti-PD-1/PD-L1 therapy of human cancer: past, present, and future
Lieping Chen et al.
JOURNAL OF CLINICAL INVESTIGATION (2015)
Intravenous siRNA Silencing of Survivin Enhances Activity of Mitomycin C in Human Bladder RT4 Xenografts
Minjian Cui et al.
JOURNAL OF UROLOGY (2015)
Second-Line Treatment of Advanced Urothelial Cancer with Paclitaxel and Everolimus in a German Phase II Trial (AUO Trial AB 35/09)
Guenter Niegisch et al.
ONCOLOGY (2015)
Genomic correlates of response to CTLA-4 blockade in metastatic melanoma
Eliezer M. Van Allen et al.
SCIENCE (2015)
Neoantigens in cancer immunotherapy
Ton N. Schumacher et al.
SCIENCE (2015)
Microenvironmental regulation of therapeutic response in cancer
Florian Klemm et al.
TRENDS IN CELL BIOLOGY (2015)
Epigenetic effects of RRx-001: a possible unifying mechanism of anticancer activity
Hongjuan Zhao et al.
ONCOTARGET (2015)
Characterization of the in vivo immune network of IDO, tryptophan metabolism, PD-L1, and CTLA-4 in circulating immune cells in melanoma
I. Chevolet et al.
ONCOIMMUNOLOGY (2015)
The Development Of RRx-001, A Novel Nitric-Oxide-Mediated Epigenetically Active Anticancer Agent
Jan Scicinski et al.
Redox Biology (2015)
The Effect of Radiation on the Immune Response to Cancers
Bonggoo Park et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2014)
NVP-BEZ235, a dual PI3K/mTOR inhibitor synergistically potentiates the antitumor effects of cisplatin in bladder cancer cells
Du G. Moon et al.
INTERNATIONAL JOURNAL OF ONCOLOGY (2014)
Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice
Liufu Deng et al.
JOURNAL OF CLINICAL INVESTIGATION (2014)
Comprehensive molecular characterization of urothelial bladder carcinoma
John N. Weinstein et al.
NATURE (2014)
Optimizing intravesical mitomycin C therapy in non-muscle-invasive bladder cancer
Homayoun Zargar et al.
NATURE REVIEWS UROLOGY (2014)
Intravesical ALT-803 and BCG Treatment Reduces Tumor Burden in a Carcinogen Induced Bladder Cancer Rat Model; a Role for Cytokine Production and NK Cell Expansion
Evan Gomes-Giacoia et al.
PLOS ONE (2014)
Epigenetic drugs as immunomodulators for combination therapies in solid tumors
Luca Sigalotti et al.
PHARMACOLOGY & THERAPEUTICS (2014)
Increased Anticancer Efficacy of Intravesical Mitomycin C Therapy when Combined with a PCNA Targeting Peptide
Odrun A. Gederaas et al.
TRANSLATIONAL ONCOLOGY (2014)
Clinical Outcome of Paclitaxel and Carboplatin as Second-Line Chemotherapy for Advanced Urothelial Carcinoma Resistant to First-Line Therapy with Gemcitabine and Cisplatin
Tomoaki Terakawa et al.
UROLOGIA INTERNATIONALIS (2014)
Multi-institutional analysis of sequential intravesical gemcitabine and mitomycin C chemotherapy for non-muscle invasive bladder cancer
Andrew J. Lightfoot et al.
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS (2014)
Abscopal effects of radiotherapy on advanced melanoma patients who progressed after ipilimumab immunotherapy
Antonio M. Grimaldi et al.
ONCOIMMUNOLOGY (2014)
Phase II study of everolimus in metastatic urothelial cancer
Matthew I. Milowsky et al.
BJU INTERNATIONAL (2013)
Dual Blockade of PD-1 and CTLA-4 Combined with Tumor Vaccine Effectively Restores T-Cell Rejection Function in Tumors
Jaikumar Duraiswamy et al.
CANCER RESEARCH (2013)
Regulation of PCNA-protein interactions for genome stability
Niels Mailand et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2013)
Programming of Regulatory T Cells from Pluripotent Stem Cells and Prevention of Autoimmunity
Rizwanul Haque et al.
JOURNAL OF IMMUNOLOGY (2012)
A phase II trial of temsirolimus in second-line metastatic urothelial cancer
H. Gerullis et al.
MEDICAL ONCOLOGY (2012)
Genome Sequencing Identifies a Basis for Everolimus Sensitivity
Gopa Iyer et al.
SCIENCE (2012)
Indoleamine 2,3-Dioxygenase Expression in Human Cancers: Clinical and Immunologic Perspectives
Jessica Godin-Ethier et al.
CLINICAL CANCER RESEARCH (2011)
Sequential Intravesical Chemoimmunotherapy with Mitomycin C and Bacillus Calmette-Guerin and with Bacillus Calmette-Guerin Alone in Patients with Carcinoma in Situ of the Urinary Bladder: Results of an EORTC Genito-Urinary Group Randomized Phase 2 Trial (30993)
Willem Oosterlinck et al.
EUROPEAN UROLOGY (2011)
Drugging the PI3 Kinome: From Chemical Tools to Drugs in the Clinic
Paul Workman et al.
CANCER RESEARCH (2010)
PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors
Michael A. Curran et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
Sequential intravesical gemcitabine and mitomycin C chemotherapy regimen in patients with non-muscle invasive bladder cancer
Benjamin N. Breyer et al.
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS (2010)
Identification of a novel, widespread, and functionally important PCNA-binding motif
Karin M. Gilljam et al.
JOURNAL OF CELL BIOLOGY (2009)
PI(3) kinase is associated with a mechanism of immunoresistance in breast and prostate cancer
C. A. Crane et al.
ONCOGENE (2009)
Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma
Andrew T. Parsa et al.
NATURE MEDICINE (2007)
Share Paper
